Oxcarbazepine Tablet
Product Images NDC 68382-692

This information shows the result of a log-rank test with a p-value of 0.0001, comparing the treatment group with oxcarbazepine to another group over a period of time on trial starting from Day 2.*

This text appears to provide information about a log-rank test with a p-value of 0.046. It also includes a timeline chart showing days from the 1st dose to the 15th seizure for two treatment groups: Oxcarbazepine and Placebo. This data may be related to a study or clinical trial involving the effectiveness of these treatments.*

This is a plot showing the time to exit in days for two treatment groups: high and low. The x-axis represents the days, and the y-axis shows the proportions of individuals exiting at that time.*

The log-rank test was performed and resulted in a p-value of 0.0001. Additionally, a sequence of numerical values is shown from 10 to 130 in increments of 10. This data might be related to a specific analysis or study.*

This is a description for Oxcarbazepine Tablets, USP. Each film-coated tablet contains 150 mg of Oxcarbazepine. The usual dosage should be checked in the package insert for complete prescribing information. It is recommended to store the tablets at a temperature between 20°C to 25°C (68°F to 77°F). The medication should be dispensed in a tight container to maintain quality. This drug should be kept out of the reach of children. The FDA-approved organic impurities acceptance criteria may differ from USP standards. The medication is manufactured by Cadila Healthcare Ltd. in Badd, India and distributed by Zydus Pharmaceuticals (USA) Inc. in Fennington, NJ 08534.*

Each film coated tablet contains 150 mg of Oxcarbazepine USP. This unit dose package with 100 tablets (10 x 10 unit-dose) is distributed by Zydus Pharmaceuticals (USA) Inc. The usual dosage information can be found in the package insert for complete prescribing details. Store the tablets at 20° to 25°C (68° to 77°F) and dispense in a tight container as defined by USP guidelines. The medication guide provided must be given to the patient. Keep this and all drugs out of the reach of children. Note that the FDA-approved organic impurities acceptance criteria differ from the USP test. Oxcarbazepine Tablets, USP are manufactured by Cadila Healthcare Ltd. in Baddi, India.*

This text is a label of a medication containing Oxcarbazepine USP 300 mg. It provides instructions for storage, dosage, and dispensing guidelines. The medication is dispensed in a tight container and must be kept out of reach of children. The manufacturer is mentioned as well. Additional information may be available in the package insert.*

This is a pharmaceutical product label for Oxcarbazepine tablets, USP, each containing 300 mg of Oxcarbazepine. The recommended storage is at 20° to 25°C. The package insert provides detailed prescribing information. The tablets come in a unit-dose package of 100 tablets (10 x 10). The manufacturer is Cadila Healthcare Ltd. from Baddi, India. The product is distributed by Zydus Pharmaceuticals (USA) Inc. in Pennington, NJ. The text also mentions the importance of keeping the medication out of reach of children and that the unit dose package is not child-resistant.*

This is the packaging information for Oxcarbazepine tablets containing 600 mg. Each film-coated tablet is imprinted with "NDC 68362-693-30". The usual dosage guidance can be found in the package insert. The tablets should be stored at 20° to 25°C (68° to 77°F). Dispensing should be done in a tight container according to USP standards. It is essential to keep this medication out of reach of children. The unit dose package is not child-resistant. The medication is manufactured by Cadila Healthcare Ltd. in Baddi, India and distributed by Zydus Pharmaceuticals (USA) Inc. in Pennington, NJ 08534.*